Literature DB >> 9692769

Modulation of airway hyperresponsiveness and eosinophilia by selective histamine and 5-HT receptor antagonists in a mouse model of allergic asthma.

J J De Bie1, P A Henricks, W W Cruikshank, G Hofman, E H Jonker, F P Nijkamp, A J Van Oosterhout.   

Abstract

1. Since both histamine and 5-hydroxytryptamine (5-HT) can be released by murine mast cells, we investigated the possible role of these autacoids on airway hyperresponsiveness (AHR), eosinophil infiltration and serum-IgE levels in a murine model of allergic asthma. 2. Ovalbumin-sensitized mice were exposed to either ovalbumin (2 mg ml(-1)) or saline aerosols on 8 consecutive days. Starting one day before the challenge, animals were injected i.p. twice a day with a 5-HT-type 1 (5-HT1) or type 2 (5-HT2) receptor antagonist (methiotepine, 1.25 or 2.0 mg kg(-1) and ketanserin, 12 mg kg(-1), respectively) or a histamine-type 1 (H1) or type 2 (H2) receptor antagonist (mepyramine, 12 or 20 mg kg(-1) and cimetidine, 10 or 25 mg kg(-1), respectively). Furthermore, animals were injected with a combination of cimetidine and ketanserin or with an alpha-adrenoceptor antagonist (phentolamine, 5 mg kg(-1)). 3. In vehicle-treated ovalbumin-challenged animals airway responsiveness to intravenous injections of methacholine in vivo was significantly (9 fold increase, P<0.01) increased when compared to vehicle-treated saline-challenged animals. Furthermore, ovalbumin challenge of vehicle-treated animals induced a significant increase in both eosinophil numbers in bronchoalveolar lavage (BAL) fluid (0+/-0, vehicle/saline and 15.0+/-5.9 x 10(4) cells vehicle/ovalbumin, P<0.05) and ovalbumin-specific IgE levels in serum (157+/-69 and 617+/-171 units ml(-1), respectively, P<0.05) compared to saline-challenged mice. Virtually no eosinophils could be detected in saline-challenged animals after all different treatments. 4. Treatment with ketanserin or cimetidine resulted in a partial but significant decrease of the ovalbumin-induced AHR compared to ovalbumin-challenged controls (P<0.05) and reduced eosinophil infiltration after ovalbumin challenge by 60% and 58%, respectively. The combination of cimetidine and ketanserin almost completely abolished AHR whereas eosinophilia was decreased by 49%. No effects of these antagonists were observed on IL-16 levels in BAL fluid or on serum antigen-specific IgE levels. Treatment with either the H1-receptor, the 5-HT1-receptor or the alpha-adrenoceptor antagonist, did not decrease the observed ovalbumin-induced airway responsiveness or eosinophilia in vehicle-treated animals. Higher doses of either methiotepine (2.0 mg kg(-1)) or mepyramine (20 mg kg(-1)) did decrease ovalbumin-induced eosinophil infiltration (by 67%, P<0.05 and 73%, respectively), whereas no effects of these antagonists were observed on ovalbumin-specific IgE levels in serum. 5. From these data it can be concluded that both histamine and 5-HT play a role in antigen-induced AHR and eosinophilia in the mouse.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9692769      PMCID: PMC1565459          DOI: 10.1038/sj.bjp.0701901

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

1.  Glycomacropeptide administration attenuates airway inflammation and remodeling associated to allergic asthma in rat.

Authors:  Nuria Renata Roldán; Mariela Jiménez; Daniel Cervantes-García; Estefanía Marín; Eva Salinas
Journal:  Inflamm Res       Date:  2016-01-11       Impact factor: 4.575

2.  The hepatic sympathetic nerve plays a critical role in preventing Fas induced liver injury in mice.

Authors:  Y Chida; N Sudo; A Takaki; C Kubo
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

3.  The dual H3/4R antagonist thioperamide does not fully mimic the effects of the 'standard' H4R antagonist JNJ 7777120 in experimental murine asthma.

Authors:  Detlef Neumann; Silke Beermann; Heike Burhenne; Silke Glage; Christina Hartwig; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-07-03       Impact factor: 3.000

4.  Alteration of airway responsiveness mediated by receptors in ovalbumin-induced asthmatic E3 rats.

Authors:  Jing-Wen Long; Xu-Dong Yang; Lei Cao; She-Min Lu; Yong-Xiao Cao
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

5.  Mast cell-dependent anorexia and hypothermia induced by mucosal activation of Toll-like receptor 7.

Authors:  Tomoko Hayashi; Howard B Cottam; Michael Chan; Guangyi Jin; Rommel I Tawatao; Brian Crain; Lisa Ronacher; Karen Messer; Dennis A Carson; Maripat Corr
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-05-14       Impact factor: 3.619

Review 6.  Novel uses for anti-platelet agents as anti-inflammatory drugs.

Authors:  S C Pitchford
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

7.  Allergic sensitization increases contractile responses to 5-HT in guinea pig aorta.

Authors:  P Campos-Bedolla; R De-La-Cruz-Negrete; M H Vargas; E Torrejón-González; D Mejía-Mendoza; A Islas-Hernández; P Segura-Medina; G Córdoba-Rodríguez; S Orozco-Suárez; J L Arreola-Ramírez
Journal:  Physiol Res       Date:  2019-12-19       Impact factor: 1.881

8.  Opposite effects of mepyramine on JNJ 7777120-induced amelioration of experimentally induced asthma in mice in sensitization and provocation.

Authors:  Silke Beermann; Silke Glage; Danny Jonigk; Roland Seifert; Detlef Neumann
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

9.  Regulation of serotonin-induced trafficking and migration of eosinophils.

Authors:  Bit Na Kang; Sung Gil Ha; Nooshin S Bahaie; M Reza Hosseinkhani; Xiao Na Ge; Malcolm N Blumenthal; Savita P Rao; P Sriramarao
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

10.  Secondhand smoke exposure causes bronchial hyperreactivity via transcriptionally upregulated endothelin and 5-hydroxytryptamine 2A receptors.

Authors:  Lei Cao; Yaping Zhang; Yong-Xiao Cao; Lars Edvinsson; Cang-Bao Xu
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.